TP53 and neoplasm: The above studies demonstrate that there remains conflicting evidence of predictive value of TP53 mutations in relation to WEE1 inhibitor, and further studies may be needed to study different TP53 inactivation mechanisms in relation to response to WEE1 inhibitor with different chemotherapies and tumor subtypes.